Neurocrine Biosciences, Inc [NBIX] stock is trading at $133.05, up 5.01%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBIX shares have gain 3.04% over the last week, with a monthly amount glided 8.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on August 29, 2024, and elevated its price target to $159. On April 24, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Deutsche Bank initiated its recommendation with a Buy and recommended $136 as its price target on December 12, 2023. In a note dated August 21, 2023, Mizuho reiterated an Neutral rating on this stock and boosted its target price from $112 to $113.
Neurocrine Biosciences, Inc [NBIX] stock has fluctuated between $110.95 and $157.98 over the past year. Currently, Wall Street analysts expect the stock to reach $156.14 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $133.05 at the most recent close of the market. An investor can expect a potential return of 17.35% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.24B for the trailing twelve months, which represents a growth of 24.72%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.16 and Total Capital is 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 128.66 points at the first support level, and at 124.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 136.13, and for the 2nd resistance point, it is at 139.20.
Ratios To Look Out For
For context, Neurocrine Biosciences, Inc’s Current Ratio is 4.37. Also, the Quick Ratio is 4.26, while the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 6.00, the price to book ratio is 4.95 and price to earnings (TTM) ratio is 35.64.
Transactions by insiders
Recent insider trading involved Onyia Jude, Chief Scientific Officer, that happened on Nov 29 ’24 when 2331.0 shares were sold. Officer, JUDE ONYIA completed a deal on Nov 29 ’24 to buy 2331.0 shares. Meanwhile, Chief Corp. Affairs Officer Boyer David W. sold 3461.0 shares on Sep 13 ’24.
